Corporate Finance
FRP Corporate Finance advises Kelso Pharma on Alturix acquisition
The acquisition of Alturix will scale Kelso’s commercial presence in the UK, supporting a long-term pan-European growth strategy via new product launches, cross-selling and in-licensing opportunities
The FRP Corporate Finance debt advisory team has supported pan-European specialist pharmaceutical business, Kelso Pharma (Kelso), on its acquisition of Alturix, a UK pharmaceutical company specialising in developing and commercialising originator and niche branded generics.
You'll need to
subscribe to unlock this content. Already subscribed? Login?
